MDT Earnings: Medtronic Stock Slips Despite Earnings Beat

Medical device company Medtronic (MDT) released its Fiscal Q4 2025 earnings report before the opening bell on Wednesday. The company posted adjusted earnings per share of $1.62, compared to Wall Street’s estimate of $1.58. This also represented an 11% increase year-over-year from adjusted earnings of $1.46 per share.

Medtronic reported revenue of $8.93 billion, better than the $8.81 billion analysts expected. The medical company’s revenue also grew 3.9% year-over-year from $8.59 billion. It saw strong growth across its Cardiovascular, Neuroscience, and Diabetes businesses.

MDT stock was down slightly in pre-market trading despite beating Fiscal Q4 2025 estimates. However, the shares remain up 8.98% year-to-date.

Big Changes Are Coming to Medtronic

Medtronic announced major changes in its latest earnings report. The company intends to separate its Diabetes business into a new standalone public company as part of an ongoing portfolio management strategy. It expects to do so through a series of capital markets transactions, with its preferred plan being an initial public offering (IPO) after the split, which should happen within the next 18 months.

Other changes for Medtronic include the departure of Cardiovascular Portfolio Executive Vice President and President Sean Salmon. He will be replaced by Skip Kiil, Senior Vice President and President of the Medtronic Cranial and Spinal Technologies business.

Finally, Medtronic announced a dividend increase. Shareholders on record as of June 27, 2025, will receive a dividend of 71 cents per share on July 11, 2025. This increased dividend will result in an annual dividend payment of $2.84 per share.

Is MDT Stock a Buy, Sell, or Hold?

Turning to Wall Street, the analysts’ consensus rating for Medtronic is Moderate Buy, based on seven Buy and seven Hold ratings over the last three months. With that comes an average price target of $96.38, representing a potential 11.59% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today’s earnings report.

See more MDT stock analyst ratings